NEW YORK (GenomeWeb News) – The Ontario Genomics Institute today said that is providing $100,000 through its Pre-commercialization Business Development Fund (PBDF) to the University of Toronto to support its Mammalian Membrane Two-Hybrid (MaMTH) project, which seeks to develop and commercialize a process to better understand membrane proteins in mammalian cells.
The technology developed by the University of Toronto researchers analyzes protein-protein interactions of mammalian integral membrane proteins. It is designed to enable researchers to study interactions between membrane proteins of interest and how they respond to various therapeutic compounds in the context of the human cell.
"There is strong demand for technologies like MaMTH from both academia and pharmaceutical companies, and this funding will enable us to make the final step in bringing this tool to market," Igor Stagljar, a UT professor in the departments of biochemistry and molecular genetics who directed development of the technology, said in a statement.